Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Wilwand

Orthopaedic Surgery Walla Walla, WA Doctor of Osteopathy

NPI 1861604217 CMS profile 1099696

55 West Tietan Street, Walla Walla, WA 99362

Open in the dashboard

General payments

$14,950

114 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Wilwand of Walla Walla, WA is reported in the CMS Open Payments database as having received $14,950 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $853 9
2024 General $2,867 19
2023 General $3,526 18
2022 General $4,337 18
2021 General $1,349 18
2020 General $856 20
2019 General $1,162 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Wilwand
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Michael Wilwand were reported at $853. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Michael Wilwand Orthopaedic Surgery median Middle half National median
2019 $1,162 $644 $140–$2,844 $163
2020 $856 $312 $75–$1,860 $114
2021 $1,349 $520 $117–$2,495 $132
2022 $4,337 $598 $128–$2,731 $149
2023 $3,526 $461 $128–$2,264 $160
2024 $2,867 $497 $134–$2,475 $164
2025 $853 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $10,219 53 payments
  2. Zimmer Biomet Holdings, Inc. $2,128 24 payments
  3. Exactech, Inc. $1,115 5 payments
  4. Arthrex, Inc. $714 15 payments
  5. Orthalign Inc $390 3 payments
  6. Summit Surgical Corp. $185 3 payments
  7. Flexion Therapeutics, Inc. $66 4 payments
  8. Invictus Surgical Incorporated $51 3 payments
  9. Endo USA, Inc. $43 2 payments
  10. SI-BONE, Inc. $20 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $10,163 33 payments
  2. Food and Beverage $4,786 81 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $6,127 23 payments
  2. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $2,723 7 payments
  3. EQUINOXE Orthopaedic $828 3 payments
  4. Comprehensive Reverse $711 5 payments
  5. Comprehensive Primary Stem $439 6 payments
  6. ORTHALIGN PLUS $390 3 payments
  7. TRIATHLON $385 5 payments
  8. Equinoxe Orthopaedic $286 2 payments
  9. INSIGNIA $247 2 payments
  10. MAKO Knees, Hips $213 7 payments
  11. Other $1,443 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

135

Median for Orthopedic Surgery: 203

Drug cost

$626

Median for Orthopedic Surgery: $1,433

Branded share of claims

16.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 85 $413
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 22 $159
Tramadol Hcl Generic 28 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$158,258

Of which drugs: $11,800

Medicare patients

327

Average age 75

Services billed

4,645

169 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 70%
High blood pressure 68%
Diabetes 25%
Chronic kidney disease 24%
Ischemic heart disease 23%
Depression 20%
Atrial fibrillation 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 29 2,726 $247
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 78 290 $213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record